Tekmira Pharmaceuticals Corporation (TKMR) Falls On Downgrade

Leerink Swann has downgraded Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) from “outperform” to “market perform” in a research note issued on Monday

TheFlyOnTheWall.com reports that Leerink Swann currently has a $30.00 price objective on the stock, up from their previous level of $25.00. The price objective would suggest a predicted upside of 25.00% from current price.

Tekmira Pharmaceuticals (NASDAQ:TKMR) has a 1-year low of $7.17 and a 1-year high of $31.48, with a trading volume of 2,319,047 shares. The shares traded up 1.66% on Monday, hitting $24.3994. The stock’s 50-day moving average is $20.7 and its 200-day moving average is $15.95.

This Tiger Cub Giant Is Betting On Banks And Tech Stocks In The Recovery

D1 CapitalThe first two months of the third quarter were the best months for D1 Capital Partners' public portfolio since inception, that's according to a copy of the firm's August update, which ValueWalk has been able to review. Q2 2020 hedge fund letters, conferences and more According to the update, D1's public portfolio returned 20.1% gross Read More

The stock saw some unusual options trading on Monday. Investors bought 13,944 call options on the company. This is an increase of around 235% compared to the average volume of 4,158 call options.

Tekmira Pharmaceuticals Corporation – Earnings reports

The last earnings report for Tekmira Pharmaceuticals (NASDAQ:TKMR) was published last Wednesday, August 13. The company reported ($0.28) EPS for the quarter, $0.02 lower than the Thomson Reuters consensus estimate of $0.26. Quarterly revenue was $1.80 million, compared to the consensus estimate of $3.72 million. Average predicted earnings per share for the current financial year are $-1.69 according to analysts.

Leerink Swann were not the only analysts to comment on the stock. In a research note published on Friday, Maxim Group raised their price target on shares from $23.00 to $31.00. The stock is now rated as “buy”. Clarus Securities had previously initiated coverage on shares in Tekmira Pharmaceuticals, setting a “buy” rating and a $22.50 price target on the stock.

Tekmira Pharmaceuticals Corporation TKMR – Average analyst ratings

Although four other analysts have given the stock a “buy” rating, one has rated it as a “sell”, and yet one more has assigned a “hold” rating. As it stands the stock has a consensus rating of “Buy” and the average target price is $28.90.

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company which focuses on advancing ribonucleic acid interference (RNAi) therapeutic, ebola ‘cures’, as well as distributing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners.

The stock suffered following the news that rival company Chimerix’s drug would be used to treat ebola patients in the U.S. Tekmira’s TKM-Ebola treatment has also been used but supplies have been limited.

Presently (3:05PM EDT), Tekmira is trading at 23.39 down 0.61 or 2.54%. Volume has already surpassed the average 90-day of 4,669,860 with 5,333,456 shares changing hands today with another hour of trading remaining.